Table 5.
Predictor | OR(95%CI) | p | a OR(95%CI) | p | |
---|---|---|---|---|---|
Age(years) | ≤45 | 1 | |||
> 45 | 0.72(0.35,1.48) | 0.367 | |||
Gender | Male | 1 | |||
Female | 0.74(0.36,1.55) | 0.431 | |||
Education degree | illiteracy | 1 | |||
Primary school | 1.23(0.44,3.44) | 0.699 | |||
Junior middle school | 0.91(0.30,2.72) | 0.865 | |||
Baseline CD4 + T cells/μl | CD4 ≤ 50 | 2.86(0.64,12.7) | 0.168 | 2.68(0.35,20.35) | 0.340 |
50 < CD4 ≤ 200 | 1.63(0.77,3,47) | 0.202 | 1.20(0.45,3.19) | 0.450 | |
CD4 > 200 | 1 | ||||
Baseline viral load copies/ml | 1000 < HIV RNA ≤ 10,000 | 1 | 1 | ||
10,000 < HIV RNA ≤ 10,000 | 1.31(0.52,3.31) | 0.567 | 1.07(0.34,3.32) | 0.914 | |
HIV RNA > 100,000 | 3.46(1.27,9.37) | 0.015 | 2.18(0.63,7.61) | 0.221 | |
Duration of first-line therapy (years) | ≤4 | 1 | |||
> 4 | 1.35(0.60,3.04) | 0.475 | |||
Baseline 3TC/TDF resistance | sensitive | 1 | 1 | ||
low/moderate resistance | 0.28(0.12,0.66) | 0.004 | 0.29(0.10,0.83) | 0.022 | |
high resistance | 0.16(0.05,0.49) | 0.001 | 0.10(0.24,0.43) | 0.002 | |
medication adherence | 90–100% | 1 | 1 | ||
< 90% | 9.98(2.00,49.89) | 0.005 | 22.74(3.38,152.59) | 0.001 | |
unknown | 7.48(2.95,18.97) | < 0.001 | 9.40(2.98,29.67) | < 0.001 |
3TC Lamivudine, TDF Tenofovir